The emergence of Shamonda virus in European livestock and the first documented human infection highlight the need for stronger veterinary surveillance, laboratory diagnostics and a coordinated One Health response.
The spread of an emerging animal virus across Europe is drawing renewed attention from veterinary authorities and public health institutions. Shamonda virus (SHAV), a midge-borne pathogen affecting cattle and other animal species, has been detected in livestock across several European countries from July 2026 on. In November, the Food and Agriculture Organization of the United Nations (FAO) reported the first ever documented human infection, identified in France.
The case marks an important development in the understanding of the virus and its potential implications for public health. Although its ability to infect humans remains poorly understood, the findings reinforce the importance of monitoring emerging animal diseases and investigating potential connections between animal, human and environmental health.
For veterinary professionals, researchers and livestock producers, the situation raises important questions about disease detection, reproductive health and general preparedness on (regional) new diseases.
The Shamonda virus and how it spreads
Shamonda virus belongs to the Simbu serogroup of viruses, within the Orthobunyavirus genus. It was first isolated from cattle in Nigeria in 1965 and has subsequently been identified in parts of Africa and Asia.
The virus is primarily transmitted through the bites of infected Culicoides biting midges, small blood-feeding insects that can act as vectors for several livestock diseases.
Cattle appear to be the main livestock hosts, although infections have also been reported in sheep, goats, horses and alpacas with the serotype SHAV-EU1. The disease has historically received limited attention outside regions where the virus was previously detected. However, its emergence in European livestock during the summer of 2026 has significantly expanded the geographical scope of surveillance.
According to FAO, animal infections have been identified in Austria, Belgium, France, Germany, Ireland, Italy, Jersey, Liechtenstein, Luxembourg, the Netherlands, Portugal, Spain and Switzerland. In October, additional detections were reported on two dairy farms in the United Kingdom, one in Wales and another in Shropshire.
Investigations have identified two distinct variants circulating in Europe: Shamonda virus Europe 1 (SHAV-EU1) and Shamonda virus Europe 2 (SHAV-EU2). They both seemed to enter Europe at the same time, SHAV-EU1 in the Alps region and SHAV-EU2 in Northwest Europe.
Clinical signs and reproductive complications in livestock
One of the main challenges associated with the Shamonda virus is that its clinical presentation can resemble other infectious diseases, making laboratory confirmation essential.
In adult cattle, infections are generally associated with relatively mild acute symptoms. However, even these cases can have significant consequences for livestock productivity, especially when coexisting with other stressors like heat or food shortage.
Reported clinical signs include:
- Fever and lethargy.
- Diarrhea and reduced appetite.
- Decreased milk production.
- Temporary production losses.
Reproductive complications represent a particularly important concern. Infection during pregnancy has been associated with abortions, stillbirths, congenital malformations and neurological abnormalities in offspring are expected as the virus is very close to the Schmallenberg-Virus that affected Europe in 2011.
These outcomes can affect herd productivity beyond the immediate period of infection, creating additional challenges for reproductive management and livestock health monitoring.
Neurological disease has also been reported in horses infected with the SHAV-EU1 variant, reinforcing the need to consider multiple susceptible species when investigating suspected cases.
Although these findings raise concerns, the full range of reproductive and long-term effects of the European variants has not yet been established.
How can the Shamonda virus be diagnosed?
As said before, laboratory testing plays a crucial role in identifying Shamonda virus infections.
Current diagnostic approaches include molecular techniques such as pan-Simbu PCR assays and virus-specific reverse transcription polymerase chain reaction (RT-PCR). These methods help detect viral genetic material and distinguish Shamonda virus from other pathogens within the same viral group. But viremia happens only for about 2 days, so often samples are taken too late.
Sequencing is also important for characterizing circulating variants and improving understanding of their geographical distribution and epidemiological behaviour. Serological testing can provide additional information about previous exposure and help differentiate related viruses.
Veterinary professionals should consider Shamonda virus as part of the differential diagnosis when investigating:
- Unexplained reproductive disorders.
- Abortions and stillbirths.
- Congenital malformations.
- Reduced milk production.
- Unexplained febrile illness in ruminants.
Collecting appropriate samples (from newly afflicted animals) and establishing effective referral pathways between veterinary services and diagnostic laboratories are essential steps in improving detection and outbreak investigations.
The first reported human infection by Shamonda virus
The first documented human infection with Shamonda virus was reported in France in October 2026, involving an individual with a severely compromised immune system.
The finding represents a significant development because the virus had not previously been recognized as a cause of human disease.
However, one reported case does not establish how frequently human infections may occur, how transmission happened, or what the broader public health implications might be. Further investigations are needed to determine the circumstances of infection and whether the virus poses a measurable risk to other populations.
The World Organisation for Animal Health (WOAH) and FAO have emphasized the importance of continued monitoring and scientific collaboration to clarify the virus’s zoonotic potential.
For now, the available evidence does not justify treating Shamonda virus as an established widespread zoonotic threat. Instead, the human case highlights the need for a more comprehensive understanding of emerging pathogens that circulate at the animal-human-environment interface.
Strengthening veterinary surveillance and biosecurity
The spread of the Shamonda virus across multiple countries demonstrates how quickly an emerging animal disease can become an international surveillance priority.
Veterinary authorities and livestock professionals play a fundamental role in identifying unusual clinical patterns, investigating suspected infections, and communicating relevant findings to diagnostic and epidemiological networks.
Several measures are particularly important:
1. Strengthening active and passive surveillance
Monitoring livestock populations, reproductive losses, congenital abnormalities, and unexplained production changes can help identify potential outbreaks earlier. Both routine veterinary inspections and reports from producers contribute to a more complete picture of disease distribution.
2. Expanding laboratory diagnostic capacity
Access to reliable molecular testing, sequencing, and trained laboratory personnel is essential for confirming infections and characterizing circulating viral variants.
3. Monitoring insect vectors
Since transmission is associated with Culicoides biting midges, entomological surveillance can help identify vector activity and environmental conditions that may influence transmission patterns.
4. Improving farm-level biosecurity
Risk-based measures, including physical barriers against biting midges, vector monitoring around livestock facilities and strategies to reduce potential breeding sites, can contribute to limiting exposure. Animal transport management during periods of high vector activity may also help reduce risks. But as we learned with the Bluetongue virus and the Schmallenberg virus in Europe, insecticides may reduce the clinical symptoms by reducing the individual virus load in a herd but will not stop the emergence of these diseases.
5. Promoting international information exchange
The movement of livestock, vectors, and emerging pathogens across borders makes communication between veterinary services, laboratories, research institutions, and public health authorities particularly important.
At present, there are no commercially available vaccines against Shamonda virus. This makes surveillance, laboratory confirmation, and preventive management especially relevant to preparedness efforts.
Summarized by the WAB in November 2026, lead authors Ricardo Jordão, WAB President, and Peter Heimberg, WAB Secretary.
References
Food and Agriculture Organization of the United Nations. (2026, November 10). Shamonda virus outbreaks continue spreading in animals in Europe with the reporting of the first human infection. fao.org
World Organisation for Animal Health. (2026, October 21). Shamonda virus: Factsheet and questions and answers. woah.org
Friedrich-Loeffler-Institut, Germany: It happened again – emergence of a Shamonda-like orthobunyavirus in Central Europe, 2026. Kerstin Wernike, Bernd Hoffmann, Ellen K. Link, Simon Rotheneder, Mirette Eshak, Florian Pfaff, Dirk Höper, Martin Beer. 10.64898/2026.08.06.743243
Friedrich-Loeffler-Institut, Germany: Two incursions, two viruses: emergence of a second novel Shamonda virus clade, Germany, 2026. Kerstin Wernike, Florian Pfaff, Sophie Zeiske, Dirk Höper, Martin Beer. 10.2807/1560-7917.ES.2026.31.39.2600756
Aulendorf State Veterinary Diagnostic Center, Germany: Detection of Shamonda virus in two horses with neurological signs in Germany. Marielle Elen Volkwein, Judith Köster, Ernst Großmann, Nathalie Hafner, Thomas Miller, Andreas Salditt, Petra Benz, Martin Beer, Angele Breithaupt, Kerstin Wernike. 10.3390/v18101125
